Evidence map›Paper›PMID 27248633›Full record

ArticleThe New England journal of medicine2016

New Agents to Treat Chronic Lymphocytic Leukemia.

Harriet S Walter, Gilles A Salles, Martin J S Dyer

3 registry-linked trialsAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in The New England journal of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01659255 phase1completednot on this map

An Open-label, Multi-Center, Non-Randomised Phase I Dose-Escalation Study to Investigate the Safety and Tolerability of ONO-4059 (ONO/GS-4059) Given as Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) and Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL)

TypeinterventionalSponsorGilead SciencesRan2012 to 2016Enrolled90ConditionsNon Hodgkins Lymphoma, Chronic Lymphocytic LeukaemiaArmsTirabrutinib
NCT02457559 phase1completednot on this map

An Open-label Study to Assess the Long-term Safety and Efficacy of ONO/GS-4059 in Subjects With Relapsed/Refractory B-cell Malignancies

TypeinterventionalSponsorGilead SciencesRan2015 to 2020Enrolled29ConditionsRelapsed/Refractory B-cell MalignanciesArmsTirabrutinib
NCT02457598 phase1terminatednot on this map

A Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib (ONO/GS-4059) in Combination With Other Targeted Anti-cancer Therapies in Subjects With B-cell Malignancies

TypeinterventionalSponsorGilead SciencesRan2015 to 2024Enrolled203ConditionsB-cell MalignanciesArmsTirabrutinib, Idelalisib, Entospletinib, Obinutuzumab
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Harriet S WalterErnest and Helen Scott Haematological Research Institute, Leicester, United Kingdom.
Gilles A SallesHospices Civils de Lyon, Lyon, France.
Martin J S DyerErnest and Helen Scott Haematological Research Institute, Leicester, United Kingdom mjsd1@le.ac.uk.

Funding

Medical Research Council MC_U132670597
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsBenzamidesFemaleHumansLeukemia, Lymphocytic, Chronic, B-CellMaleProtein-Tyrosine KinasesPyrazinesAntineoplastic AgentsBenzamidesProtein-Tyrosine KinasesPyrazines

Identifiers

PMID27248633

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.